It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

Published Date: 28 Jun 2023

Physicians can personalize dosing intervals and significantly enhance patient outcomes by tracking early-response biomarkers in men receiving 177Lu-PSMA prostate cancer therapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New drug combination shows particularly good results in patients with HPV-negative head and neck cancer

2.

Early palliative care billing up from 2010 to 2019 for advanced cancer

3.

GFR-TKIs taken orally in cancer patients who have artery dissection and aneurysms.

4.

Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers

5.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot